Invitae Corporation (NVTA)

NYSE: NVTA · IEX Real-Time Price · USD
2.52
+0.22 (9.57%)
Aug 8, 2022 4:00 PM EDT - Market closed
9.57%
Market Cap 577.81M
Revenue (ttm) 480.52M
Net Income (ttm) -451.37M
Shares Out 229.29M
EPS (ttm) -2.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 14,175,370
Open 2.37
Previous Close 2.30
Day's Range 2.26 - 2.73
52-Week Range 1.83 - 32.93
Beta 1.81
Analysts Buy
Price Target 6.20 (+146.0%)
Earnings Date Aug 9, 2022

About NVTA

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development,... [Read more...]

Industry Biotechnology
IPO Date Feb 12, 2015
Employees 2,900
Stock Exchange NYSE
Ticker Symbol NVTA
Full Company Profile

Financial Performance

In 2021, Invitae's revenue was $460.45 million, an increase of 64.68% compared to the previous year's $279.60 million. Losses were -$379.01 million, -37.06% less than in 2020.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for NVTA stock is "Buy." The 12-month stock price forecast is 6.2, which is an increase of 146.03% from the latest price.

Price Target
$6.2
(146.03% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Invitae to Announce Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

SAN FRANCISCO , Aug. 2, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2022 financial results on Tuesday, August 9,...

Why Invitae Health Stock Plummeted This Week

An analyst downgrades his recommendation on the stock, making a brutal cut to his price target while doing so.

Will Invitae (NVTA) Report Negative Q2 Earnings? What You Should Know

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Invitae Stock Crashed Today

The genetic-testing company had a lot of news that investors didn't like.

Invitae (NVTA) Stock Falls 12% on Cost-Cutting Plan

Invitae (NVTA) stock is falling on Tuesday after the biotechnology company revealed plans to cut costs as part of a strategic realignment. The post Invitae (NVTA) Stock Falls 12% on Cost-Cutting Plan ap...

Invitae Outlines Cost Saving Plan, Leadership Transition

Invitae Corp (NYSE: NVTA) plans to focus its resources on higher-margin and higher-growth businesses, including oncology, women's health, rare disease, and pharmacogenomics.  It will also continue to in...

Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow and Realize Full Potent...

—   Exiting non-core businesses and geographies to prioritize higher-margin business initiatives — —   Expects to deliver approximately $326 million in non-GAAP annualized cost savings in 2023 — —   Pro...

Invitae Announces Leadership Transition

—   COO Kenneth D. Knight named CEO succeeding Sean George; Dr. George to continue as member of Board of Directors — —   Co-Founder and former CEO Randy Scott returns as chairman — —   Current chairman ...

Bears are Losing Control Over Invitae (NVTA), Here's Why It's a 'Buy' Now

Invitae (NVTA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend...

Worldwide Clinical Trials Enters Into a Strategic Collaboration With Invitae to Accelerate Clinical Trials for Rare D...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- #CRO--Worldwide Clinical Trials announces partnership with Invitae to improve global research with enhanced data insights for rare disease studies.

Bear Market or Not, You Shouldn't Inherit This Stock's Problems

Invitae's problems make the stock a speculative lottery ticket.

Penny Stocks To Buy Now? 4 Biotech Stocks To Watch Before July 2022

Biotech penny stocks to watch right now. The post Penny Stocks To Buy Now?

Other symbols: BNTCCLVSTCRT

Why Invitae Stock Plummeted by 15% Today

Investors are taking a new, bearish analyst view on the company to heart.

3 Stocks Wall Street Thinks Could Triple Your Money or Better

Find out why the pros think these stocks could gain 200% or better.

Other symbols: AMRSLOVE

Invitae to Present at Upcoming Investor Conferences

SAN FRANCISCO , May 27, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in the following investor conf...

New Research Demonstrates Genetic Information Can Transform Cancer Care, Guidelines Remain a Barrier to Patient Access

- New data to be presented by Invitae at 2022 ASCO Annual Meeting show importance of genetic testing for all cancer patients - SAN FRANCISCO , May 26, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leadin...

3 Biotech Stocks With a Cash Pile Higher Than Their Valuations

Our roundtable found three biotechs with a nice cash cushion.

Other symbols: AGENOMIC

Invitae Launches Expanded Pharmacogenomics Panel and Specialized Mental Health Panel

- New 38-gene testing panel and clinical decision support tool analyzes a patient's genetics and co-medications for their impact on drug and dose personalization - SAN FRANCISCO , May 19, 2022 /PRNewswi...

Cathie Wood Just Bought More Invitae (NVTA) Stock. Here's Why.

Despite being down more than 60% year-to-date, Cathie Wood's Ark Invest remains confident in its thesis behind NVTA stock. The post Cathie Wood Just Bought More Invitae (NVTA) Stock.

Why Invitae Stock Is Tumbling Today

The medical genetics company reported disappointing Q1 results.

Invitae (NVTA) Reports Q1 Loss, Lags Revenue Estimates

Invitae (NVTA) delivered earnings and revenue surprises of -1.30% and 2.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Invitae Reports $123.7 Million in Revenue in First Quarter of 2022 and Extends Cash Runway

— Executing toward 2022 plan, generating near 20% revenue growth, with $885 million in ending cash*, an annualized burn reduction of greater than $100 million — — Broad OPEX controls and portfolio optim...

Allelica Collaborates with Invitae to Build Ancestry-Informed Polygenic Risk Score for Breast Cancer

Allelica and Invitae aim to decrease the gap in polygenic risk score (PRS) performance in individuals from diverse genetic ancestries, ensuring that the life-saving integration of genomic information in...

10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?

Are these Cathie Wood penny stocks a buy right now? The post 10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?

2 Healthcare Stocks That Could Go Parabolic

These two companies are poised for a comeback.

Other symbols: FIGS